Barclays PLC Lowers Stake in Alnylam Pharmaceuticals, Inc. $ALNY

Barclays PLC lowered its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 93.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 94,408 shares of the biopharmaceutical company’s stock after selling 1,267,650 shares during the period. Barclays PLC owned approximately 0.07% of Alnylam Pharmaceuticals worth $43,050,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Root Financial Partners LLC purchased a new position in Alnylam Pharmaceuticals during the third quarter valued at $25,000. Salomon & Ludwin LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the third quarter worth $27,000. Aster Capital Management DIFC Ltd bought a new position in shares of Alnylam Pharmaceuticals during the third quarter valued at $36,000. ORG Partners LLC increased its holdings in shares of Alnylam Pharmaceuticals by 70.2% during the third quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 33 shares in the last quarter. Finally, Quent Capital LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter worth about $39,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Tolga Tanguler sold 1,598 shares of the firm’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total value of $523,584.70. Following the transaction, the executive vice president directly owned 36,606 shares in the company, valued at $11,993,955.90. This trade represents a 4.18% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Yvonne Greenstreet sold 6,799 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total value of $2,227,692.35. Following the completion of the sale, the chief executive officer directly owned 98,628 shares of the company’s stock, valued at $32,315,464.20. The trade was a 6.45% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 53,923 shares of company stock worth $18,072,087 in the last 90 days. Insiders own 1.20% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

NASDAQ ALNY opened at $323.53 on Tuesday. Alnylam Pharmaceuticals, Inc. has a one year low of $205.87 and a one year high of $495.55. The stock has a 50-day moving average of $350.74 and a 200 day moving average of $413.17. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.71 and a current ratio of 2.76. The company has a market capitalization of $42.91 billion, a price-to-earnings ratio of 189.20 and a beta of 0.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.43 by ($0.18). The company had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $1.16 billion. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. Alnylam Pharmaceuticals’s revenue was up 84.9% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.65) EPS. On average, sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analyst Upgrades and Downgrades

ALNY has been the topic of a number of analyst reports. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Thursday, January 15th. Stifel Nicolaus lifted their target price on shares of Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. HC Wainwright reiterated a “buy” rating and issued a $510.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 18th. Royal Bank Of Canada cut their price target on shares of Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating on the stock in a report on Tuesday, January 20th. Finally, Leerink Partners reduced their price target on shares of Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating for the company in a research report on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $477.96.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.